ARTIDE
@artide.eu
Autoantigen-specific Regulatory T cell therapy against Type 1 Diabetes (ARTiDe) will make a unique contribution to the understanding of autoimmunity in humans and the development of antigen-specific immunotherapy. ARTiDe has the ambition to take the lead in the restoration of long-lasting immune tolerance in Type 1 Diabetes (T1D) patients, aiming to provide a cure for this disease.
ARTIDE's Company Logos
ARTIDE's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#2D2E7F
Astronaut
45, 46, 127
239, 48, 34
65, 64, 0, 50
#C5CFF0
Spindle
197, 207, 240
226, 59, 86
18, 14, 0, 6
#10236D
Deep Koamaru
16, 35, 109
228, 74, 25
85, 68, 0, 57
About ARTIDE
ARTiDe is a pioneering brand dedicated to advancing antigen-specific cellular therapy for type 1 diabetes. With the mission of revolutionizing treatment for this debilitating disease, ARTiDe aims to establish a generic production process for a groundbreaking clinical trial. By harnessing the power of autoantigen-specific Regulatory T cell therapy, ARTiDe seeks to deepen the understanding of autoimmunity and develop targeted immunotherapy solutions.
As a leader in restoring immune tolerance in Type 1 Diabetes patients, ARTiDe is at the forefront of providing a potential cure for this condition. With a focus on Regulatory T cells (Tregs) and overcoming challenges in production processes, ARTiDe is driven by a real synergy between academic and industrial partners. By setting up a GMP-compliant autoreactive Treg production process, ARTiDe is poised to launch a phase I clinical trial, offering hope to those affected by Type 1 Diabetes
